X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview

X4 Pharmaceuticals

11/11/2024 15:37

* X4 Pharmaceuticals Inc  XFOR.OQ   XFOR.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
13 for the period ending September 30 2024
    * The Boston Massachusetts-based  company is expected to
report
revenue of $1.694 million, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for X4 Pharmaceuticals Inc
is for
a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $5.00​, above​ its last closing price
of $0.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  0.13        0.01       -0.07     Missed  -1,325
                                                        .9
 Mar. 31 2024  -0.15       -0.16      -0.26     Missed  -59.6
 Dec. 31 2023  -0.17       -0.15      -0.10     Beat    34.6​
 Sep. 30 2023  -0.15       -0.15      -0.01     Beat    93.3
 ​​Jun.        -0.16       -0.16      -0.33     Missed  -102
 30 2023                                                
 Mar. 31 2023  -0.21       -0.22      -0.16     Beat    26.3​
 Jan. 1 0001   -0.21       -0.24      -0.29     Missed  -20.2
 Sep. 30 2022  -0.31       -0.30      -0.26     Beat    13.1
 This summary was machine generated November 11 at 15:37 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)